Track Your Inflammatory Arc on GLP-1 Therapy
Whether you are on Ozempic, Wegovy, Mounjaro, or Zepbound, GLP-1 medications reshape systemic biology. Powered by the Inflammation Compass™ from Biomeme Labs, our whole-blood RNA sequencing test reads thousands of genes across 3 Health Domains — Activation, Antiviral Response, and Resolution — giving you and your clinician an objective window into how your inflammatory program responds over time.
Why Molecular Monitoring Matters on GLP-1 Therapy
GLP-1 medicines reliably lower systemic inflammation markers like hs-CRP (by 35–48% in clinical trials). But CRP is just a single liver protein — an echo of the alarm phase that cannot tell you which immune cells changed or whether the response is finishing. Whole-blood transcriptomics provides a pathway-level window into the inflammatory program itself.
Early & Weight-Independent Effects
In landmark trials like SELECT, inflammatory markers dropped within 4–8 weeks — long before major weight loss took hold. While fat loss drives long-term calming, transcriptomics tracks the early, weight-independent quieting of innate cellular activation that standard blood tests blur together.
Activation Domain Calming
Circulating monocytes and neutrophils carry out acute and vascular inflammation. The Inflammation Compass reads innate danger sensors (TLRs), IL-1 and TNF signaling cascades, and monocyte trafficking modules to confirm your systemic inflammatory machinery is actively settling.
Reading the Resolution Phase
Conventional tests only ask how loud the alarm is. They are completely blind to resolution — the active biological program that stands inflammation down and clears debris. High Activation with Resolution engaged reflects a healthy response; high Activation with Resolution flat flags chronic stress.
The Off-Ramp & Epigenetic Memory
Over 60% of people discontinue GLP-1s within a year, and inflammatory recurrence is common. Because adipose tissue retains an epigenetic memory of obesity even after weight loss, monitoring before and after dose changes or discontinuation shows whether your inflammatory gains are holding.
Explore the Off-Ramp Evidence →
The Off-Ramp Is a Bigger Moment
Than the On-Ramp
While clinical trial headlines and media coverage focus almost entirely on starting GLP-1 therapy, real-world registry data demonstrates that the majority of patients discontinue within one to three years. When medications are tapered or stopped, dormant obesity-associated inflammatory programs can reactivate weeks before weight regain is visible.
The Discontinuation Cliff
Truveta & Prime Therapeutics Registries
Clinical trials keep participants on therapy under controlled conditions. But in routine clinical practice, discontinuation is the norm rather than the exception:
Adipose Epigenetic Memory
Hinte et al., ETH Zürich & Karolinska
Why is weight regain and inflammatory return so rapid following drug cessation? A landmark 2024 study published in Nature provided the molecular answer:
The Transcriptomic Compass
Objective Surveillance During Tapering
The bathroom scale and solitary liver tests like hs-CRP are lagging indicators — they only detect trouble after metabolic rebound has taken place:
Navigating the GLP-1 Off-Ramp
Discontinuing or tapering a GLP-1 without molecular monitoring means waiting for weight regain or symptoms to signal that biology has shifted. With whole-blood transcriptomics, you and your clinician have objective immune data to evaluate stability at every step.
The Unmonitored Off-Ramp
Taper or stop → Assume all is well while weight holds → Adipose epigenetic memory silently triggers inflammatory signaling → React only after scale weight rebounds.
The Transcriptomic Off-Ramp
Document maintenance baseline → Taper under clinician guidance → Re-test at 3–6 months to confirm Activation is quiet and Resolution remains autonomous → Keep gains holding.
Everything You Need to Monitor Smarter
Explore our guides across clinical evidence, biomarker comparisons, testing schedules, and realistic body composition perspectives.
Ozempic & Wegovy Blood Tests
The specific panels recommended for semaglutide users — from baseline through maintenance.
Learn moreGLP-1 Biomarkers
The molecular markers that matter most — what each one reveals about your GLP-1 response, and what to watch for.
Learn moreWhen to Get Tested
A clear testing timeline — baseline, titration checkpoints, and ongoing maintenance schedules.
Learn moreThe mRNA Layer
Go beyond standard labs. mRNA profiling reads your cells' real-time gene activity to catch changes weeks before traditional markers move.
Learn moreHow It Works
Getting started with GLP-1 molecular monitoring is straightforward. No referral required — no clinic visits, ever.
Order Online
Choose your monitoring package and place your order directly — no referral needed.
Receive Your Kit
Your collection kit ships to your door with everything needed for your mobile phlebotomy appointment.
At-Home Blood Draw
A licensed mobile phlebotomist comes to you — available across 42 states with mobile phlebotomy (excludes CA, CT, MA, MD, NJ, NY, PA, and RI due to state direct-access testing regulations).
Molecular Analysis
Your sample is processed at our CLIA-certified lab for mRNA analysis.
Results on Dashboard
Review clear, pathway-resolved results on your personal dashboard within ~1 month. Share insights directly with your provider.
Start Monitoring Your
GLP-1 Response Today
Don't fly blind on Ozempic, Wegovy, Mounjaro, or Zepbound. Starting at $600 for your 2-node baseline package, with optional continuous monitoring at $250 per node.